의약품 판매 수탁기관 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 치료 분야별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Pharmaceutical Contract Sales Organizations Market Growth & Trends:

The global pharmaceutical contract sales organizations market size is estimated to reach USD 18.14 billion by 2030, expanding at a CAGR of 8.83% from 2025 to 2030, according to a new report by Grand View Research, Inc. High adoption of new technologies for contract sales by pharmaceutical contract sales organizations (CSO), an increase in the interest among end-users to increase the sales of biopharmaceutical and small molecule drugs, and the surge in demand for reducing the cost associated with in-house sales are some of the key factors supporting the growth of the industry. Over the years, the number of new drug launches has increased.

For instance, according to the IQVIA report on R&D trends, 84 new active substances were launched globally in 2021, which was double as compared to the last five years. The increase in drug launches globally is expected to improve the demand for contract sales services, which is likely to support industry growth. Prescription drug sales are witnessing a steady rise. For instance, according to Evaluate Pharma, worldwide total prescription drug sales accounted for USD 1,066 billion in 2021 and will reach USD 1,612 billion by 2028. The growing demand for sales among pharmaceutical companies is expected to improve the demand for CSO services for pharmaceuticals in the post-pandemic period.

Pharmaceutical Contract Sales Organizations Market Report Highlights:

• Based on service, the personal promotion segment dominated the industry in 2024. A rise in the R&D activities of pharmaceutical companies is expected to increase the number of new drug launches, and approvals are expected to support the segment growth
• The pharmaceutical companies end-use segment held the largest revenue share in 2024 due to the high competition among pharmaceutical companies in product sales, promoting the demand for an efficient team to support their sales activities
• North America held the largest revenue share in 2024. A significant number of drugs were launched in the region in the previous years, especially in the U.S., which is one of the key factors supporting the region's growth
• Moreover, the region's public organization is steadily focused on supporting R&D activities by providing funding. This has further supported the region's growth

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Information Analysis
  • 1.3.1. Market Formulation & Data Visualization
• 1.4. Data Validation & Publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Industry Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
  • 3.4.2. PESTEL Analysis
  • 3.4.3. COVID-19 Impact Analysis

Chapter 4. Pharmaceutical Contract Sales Organizations Market: Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Pharmaceutical Contract Sales Organizations Market; Service Movement Analysis
• 4.3. Pharmaceutical Contract Sales Organizations Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
• 4.4. Personal Promotion
  • 4.4.1. Personal promotion market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Promotional sales team
    • 4.4.2.1. Promotional sales team market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Key account management
    • 4.4.3.1. Key account management market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Vacancy management
    • 4.4.4.1. Vacancy management market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Non-personal promotion
  • 4.5.1. Non-personal promotion market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Medical affairs solutions
    • 4.5.2.1. Medical affairs solutions market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Remote medical science liaisons
    • 4.5.3.1. Remote medical science liaisons market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Nurse educators
    • 4.5.4.1. Nurse educators market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical Contract Sales Organizations Market: Therapeutic Areas Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Pharmaceutical Contract Sales Organizations Market; Therapeutic Areas Movement Analysis
• 5.3. Pharmaceutical Contract Sales Organizations Market Size & Trend Analysis, by Therapeutic Areas, 2018 to 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Cardiovascular
  • 5.5.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Neurology
  • 5.6.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Infectious Diseases
  • 5.7.1. Infectious Diseases market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Metabolic Disorders
  • 5.8.1. Metabolic Disorders market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Orthopedic Diseases
  • 5.9.1. Orthopedic Diseases market estimates and forecasts 2018 to 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmaceutical Contract Sales Organizations Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Pharmaceutical Contract Sales Organizations Market; End Use Movement Analysis
• 6.3. Pharmaceutical Contract Sales Organizations Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical Companies
  • 6.4.1. Pharmaceutical market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Biopharmaceutical Companies
  • 6.5.1. Biopharmaceutical Companies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. North America pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Germany pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.3. UK
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. UK pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. South Korea pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Australia pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Thailand pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. CMIC Holdings Co., Ltd.
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Axxelus
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. EPS Corp.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. QFR Solutions
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. MaBico
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Mednext Pharma Pvt. Ltd.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Peak Pharma Solutions Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. IQVIA, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Promoveo Health
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Syneous Health
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives